AACP
CPRX

Advantage Alpha Capital Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,313
Closed -$262K – 31
2025
Q3 		$262K Sell
13,313
-2,887
-18% -$59.4K 0.08% 120
2025
Q2 		$352K Sell
16,200
-3,837
-19% -$90.6K 0.09% 107
2025
Q1 		$486K Buy
20,037
+6,987
+54% +$157K 0.12% 99
2024
Q4 		$272K Sell
13,050
-12,146
-48% -$261K 0.06% 142
2024
Q3 		$501K Sell
25,196
-12,124
-32% -$225K 0.11% 123
2024
Q2 		$578K Buy
+37,320
New +$581K 0.13% 98

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advantage Alpha Capital Partners's CPRX Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 13,313 shares — an estimated $262K sold.

Advantage Alpha Capital Partners first reported a position in CPRX in Q2 2024 and held it in 6 quarters. The position peaked at $578K in Q2 2024. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 13,313 Catalyst Pharmaceutical shares in Q4 2025, an estimated $262K.
  • Advantage Alpha Capital Partners first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 6 quarters.
  • Advantage Alpha Capital Partners's Catalyst Pharmaceutical position peaked at $578K in Q2 2024.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.